| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Deepti Putcha, Yuta Katsumi, Michael Brickhouse, Ryn Flaherty, David H Salat, Alexandra Touroutoglou, Bradford C Dickerso. Gray to white matter signal ratio as a novel biomarker of neurodegeneration in Alzheimer's disease. NeuroImage. Clinical. vol 37. 2022-12-31. PMID:36586361. |
alzheimer's disease (ad) is characterized neuropathologically by β-amyloid (aβ) plaques, hyperphosphorylated tau neurofibrillary tangles, and neurodegeneration, which lead to a phenotypically heterogeneous cognitive-behavioral dementia syndrome. |
2022-12-31 |
2023-08-14 |
Not clear |
| Jiasi Yu, Dan Wu, Yanan Zhao, Linli Guo, Ping Li. Study on multi-target effects of PIMPC on Aβ/Cu Brain research. 2022-12-31. PMID:36586663. |
study on multi-target effects of pimpc on aβ/cu glycogen synthase kinase-3 (gsk-3), a key role in the pathogenesis of alzheimer's disease (ad), has been linked with the formation of β-amyloid (aβ), tubulin-associated unit (tau) protein phosphorylation and apoptosis. |
2022-12-31 |
2023-08-14 |
Not clear |
| Kyu Hwan Shim, Min Ju Kang, Young Chul Youn, Seong Soo A An, SangYun Ki. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease. Alzheimer's research & therapy. vol 14. issue 1. 2022-12-31. PMID:36587215. |
alpha-synuclein: a pathological factor with aβ and tau and biomarker in alzheimer's disease. |
2022-12-31 |
2023-08-14 |
Not clear |
| Kyu Hwan Shim, Min Ju Kang, Young Chul Youn, Seong Soo A An, SangYun Ki. Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer's disease. Alzheimer's research & therapy. vol 14. issue 1. 2022-12-31. PMID:36587215. |
since idps may have distinctive functions depending on their structures, α-syn can play different roles and interact with several proteins, including amyloid-beta (aβ) and tau, in alzheimer's disease (ad) and other neurodegenerative disorders. |
2022-12-31 |
2023-08-14 |
Not clear |
| Han Gao, Ye Zhou, Peng-Shuai Jin, Dong-Gui Wu, Yu-Na Wang, Xi Zhao, Bei Zha. Molecular alteration of the proteasome contributes to AD-like pathology in the brain of HFD-STZ diabetic rats. Metabolic brain disease. 2022-12-29. PMID:36580191. |
furthermore, lactacystin were used to inhibit proteasomal activity in vivo and typical alzheimer's disease (ad)-like pathologies were detected, including amyloid-beta, tau phosphorylation, and oxidative protein changes. |
2022-12-29 |
2023-08-14 |
rat |
| Zhi-Bo Wang, Ya-Hui Ma, Yan Sun, Lan Tan, Hui-Fu Wang, Jin-Tai Y. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease. Journal of neuroinflammation. vol 19. issue 1. 2022-12-28. PMID:36578067. |
interleukin-3 is associated with strem2 and mediates the correlation between amyloid-β and tau pathology in alzheimer's disease. |
2022-12-28 |
2023-08-14 |
mouse |
| Randall J Eck, Rebecca L Kow, Aristide H Black, Nicole F Liachko, Brian C Kraeme. SPOP loss of function protects against tauopathy. Proceedings of the National Academy of Sciences of the United States of America. vol 120. issue 1. 2022-12-27. PMID:36574656. |
in the most common tauopathy, alzheimer's disease (ad), the accumulation of pathological tau strongly correlates with cognitive decline. |
2022-12-27 |
2023-08-14 |
Not clear |
| Melissa E Murray, Christina M Moloney, Naomi Kouri, Jeremy A Syrjanen, Billie J Matchett, Darren M Rothberg, Jessica F Tranovich, Tiffany N Hicks Sirmans, Heather J Wiste, Baayla D C Boon, Aivi T Nguyen, R Ross Reichard, Dennis W Dickson, Val J Lowe, Jeffrey L Dage, Ronald C Petersen, Clifford R Jack, David S Knopman, Prashanthi Vemuri, Jonathan Graff-Radford, Michelle M Mielk. Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. Molecular neurodegeneration. vol 17. issue 1. 2022-12-27. PMID:36575455. |
global neuropathologic severity of alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. |
2022-12-27 |
2023-08-14 |
human |
| Melissa E Murray, Christina M Moloney, Naomi Kouri, Jeremy A Syrjanen, Billie J Matchett, Darren M Rothberg, Jessica F Tranovich, Tiffany N Hicks Sirmans, Heather J Wiste, Baayla D C Boon, Aivi T Nguyen, R Ross Reichard, Dennis W Dickson, Val J Lowe, Jeffrey L Dage, Ronald C Petersen, Clifford R Jack, David S Knopman, Prashanthi Vemuri, Jonathan Graff-Radford, Michelle M Mielk. Global neuropathologic severity of Alzheimer's disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels. Molecular neurodegeneration. vol 17. issue 1. 2022-12-27. PMID:36575455. |
advances in ultrasensitive detection of phosphorylated tau (p-tau) in plasma has enabled the use of blood tests to measure alzheimer's disease (ad) biomarker changes. |
2022-12-27 |
2023-08-14 |
human |
| Louise Bryan, Saurabh Awasthi, Yuanjie Li, Peter Niraj Nirmalraj, Sandor Balog, Jerry Yang, Michael Maye. Site-Specific C-Terminal Fluorescent Labeling of Tau Protein. ACS omega. vol 7. issue 50. 2022-12-26. PMID:36570287. |
formation of tau protein aggregates in neurons is a pathological hallmark of several neurodegenerative diseases, including alzheimer's disease. |
2022-12-26 |
2023-08-14 |
Not clear |
| Youssra K Al-Hilaly, Connor Hurt, Janet E Rickard, Charles R Harrington, John M D Storey, Claude M Wischik, Louise C Serpell, Ansgar B Sieme. Solid-state NMR of paired helical filaments formed by the core tau fragment tau(297-391). Frontiers in neuroscience. vol 16. 2022-12-26. PMID:36570831. |
aggregation of the tau protein into fibrillar cross-β aggregates is a hallmark of alzheimer's diseases (ad) and many other neurodegenerative tauopathies. |
2022-12-26 |
2023-08-14 |
Not clear |
| Anna Rubinski, Simon Frerich, Rainer Malik, Nicolai Franzmeier, Alfredo Ramirez, Martin Dichgans, Michael Ewer. Polygenic effect on tau pathology progression in Alzheimer's disease. Annals of neurology. 2022-12-26. PMID:36571564. |
polygenic effect on tau pathology progression in alzheimer's disease. |
2022-12-26 |
2023-08-14 |
Not clear |
| David Aguillon, Stephanie Langella, Yinghua Chen, Justin S Sanchez, Yi Su, Clara Vila-Castelar, Daniel Vasquez, Henrik Zetterberg, Oskar Hansson, Jeffrey L Dage, Shorena Janelidze, Kewei Chen, Joshua T Fox-Fuller, Paula Aduen, Jairo E Martinez, Gloria Garcia, Ana Baena, Claudia Guzman, Keith A Johnson, Reisa A Sperling, Kaj Blennow, Eric M Reiman, Francisco Lopera, Yakeel T Quiro. Plasma p-tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022-12-26. PMID:36571821. |
plasma-measured tau phosphorylated at threonine 217 (p-tau217) is a potential non-invasive biomarker of alzheimer's disease (ad). |
2022-12-26 |
2023-08-14 |
Not clear |
| George Anderso. Why Do Anti-Amyloid Beta Antibodies not work? Time to reconceptualize Dementia Pathophysiology by incorporating astrocyte melatonergic pathway desynchronization from amyloid-beta production. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2022-12-26. PMID:36571832. |
recent work has challenged the classical, long-standing conceptualization of alzheimer's disease pathophysiology as driven by amyloid-β plaques and hyperphosphorylated tau tangles, including the treatments thereby derived. |
2022-12-26 |
2023-08-14 |
Not clear |
| Fernando Gonzalez-Ortiz, Michael Turton, Przemysław R Kac, Denis Smirnov, Enrico Premi, Roberta Ghidoni, Luisa Benussi, Valentina Cantoni, Claudia Saraceno, Jasmine Rivolta, Nicholas J Ashton, Barbara Borroni, Douglas Galasko, Peter Harrison, Henrik Zetterberg, Kaj Blennow, Thomas K Karikar. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain : a journal of neurology. 2022-12-26. PMID:36572122. |
brain-derived tau: a novel blood-based biomarker for alzheimer's disease-type neurodegeneration. |
2022-12-26 |
2023-08-14 |
human |
| Fernando Gonzalez-Ortiz, Michael Turton, Przemysław R Kac, Denis Smirnov, Enrico Premi, Roberta Ghidoni, Luisa Benussi, Valentina Cantoni, Claudia Saraceno, Jasmine Rivolta, Nicholas J Ashton, Barbara Borroni, Douglas Galasko, Peter Harrison, Henrik Zetterberg, Kaj Blennow, Thomas K Karikar. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain : a journal of neurology. 2022-12-26. PMID:36572122. |
blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic accuracies and agreements with their corresponding csf and neuroimaging biomarkers in the amyloid/tau/neurodegeneration [a/t/(n)] framework for alzheimer's disease. |
2022-12-26 |
2023-08-14 |
human |
| Fernando Gonzalez-Ortiz, Michael Turton, Przemysław R Kac, Denis Smirnov, Enrico Premi, Roberta Ghidoni, Luisa Benussi, Valentina Cantoni, Claudia Saraceno, Jasmine Rivolta, Nicholas J Ashton, Barbara Borroni, Douglas Galasko, Peter Harrison, Henrik Zetterberg, Kaj Blennow, Thomas K Karikar. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain : a journal of neurology. 2022-12-26. PMID:36572122. |
blood-based brain-derived tau showed equivalent diagnostic performance as csf total-tau and csf brain-derived tau to separate biomarker-positive alzheimer's disease participants from biomarker-negative controls. |
2022-12-26 |
2023-08-14 |
human |
| Fernando Gonzalez-Ortiz, Michael Turton, Przemysław R Kac, Denis Smirnov, Enrico Premi, Roberta Ghidoni, Luisa Benussi, Valentina Cantoni, Claudia Saraceno, Jasmine Rivolta, Nicholas J Ashton, Barbara Borroni, Douglas Galasko, Peter Harrison, Henrik Zetterberg, Kaj Blennow, Thomas K Karikar. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain : a journal of neurology. 2022-12-26. PMID:36572122. |
furthermore, plasma brain-derived tau accurately distinguished autopsy-confirmed alzheimer's disease from other neurodegenerative diseases (area under the curve = 86.4%) while neurofilament light did not (area under the curve = 54.3%). |
2022-12-26 |
2023-08-14 |
human |
| Fernando Gonzalez-Ortiz, Michael Turton, Przemysław R Kac, Denis Smirnov, Enrico Premi, Roberta Ghidoni, Luisa Benussi, Valentina Cantoni, Claudia Saraceno, Jasmine Rivolta, Nicholas J Ashton, Barbara Borroni, Douglas Galasko, Peter Harrison, Henrik Zetterberg, Kaj Blennow, Thomas K Karikar. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain : a journal of neurology. 2022-12-26. PMID:36572122. |
these results were further verified in two memory clinic cohorts where serum brain-derived tau differentiated alzheimer's disease from a range of other neurodegenerative disorders, including frontotemporal lobar degeneration and atypical parkinsonian disorders (area under the curve up to 99.6%). |
2022-12-26 |
2023-08-14 |
human |
| Fernando Gonzalez-Ortiz, Michael Turton, Przemysław R Kac, Denis Smirnov, Enrico Premi, Roberta Ghidoni, Luisa Benussi, Valentina Cantoni, Claudia Saraceno, Jasmine Rivolta, Nicholas J Ashton, Barbara Borroni, Douglas Galasko, Peter Harrison, Henrik Zetterberg, Kaj Blennow, Thomas K Karikar. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain : a journal of neurology. 2022-12-26. PMID:36572122. |
notably, plasma/serum brain-derived tau correlated with neurofilament light only in alzheimer's disease but not in the other neurodegenerative diseases. |
2022-12-26 |
2023-08-14 |
human |